Brief: MEI Pharma And Kyowa Kirin Announce Discontinuation Of Zandelisib Development Outside Of Japan
05/12/2022 22:29
Dec 5 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* MEI PHARMA AND KYOWA KIRIN ANNOUNCE DISCONTINUATION OF
ZANDELISIB DEVELOPMENT OUTSIDE OF JAPAN FOLLOWING RECENT FDA
MEETING
* DISCONTINUING GLOBAL DEVELOPMENT OF ZANDELISIB OUTSIDE OF
JAPAN
FOR B-CELL MALIGNANCIES
* KYOWA KIRIN IS CONTINUING ONGOING CLINICAL TRIALS
INCLUDING
PHASE 2 MIRAGE STUDY
* KYOWA KIRIN WILL EXPLORE POTENTIAL FOR A SUBMISSION TO
JAPANESE
HEALTH AUTHORITIES BASED ON DATA FROM MIRAGE AND TIDAL TRIALS
Source text for Eikon: ID:nBw32gQr9a
Further company coverage: 4151.T
((Reuters.Briefs@thomsonreuters.com))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations